On July 18, 2023 Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy-based on its proprietary Alluminox platform, reported that it will host a virtual R&D Day on the preliminary safety and efficacy findings from its open-label Phase 1b/2 study of Alluminox treatment using ASP-1929 in combination with anti-PD-1 therapy in recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) (Press release, Rakuten Medical, JUL 18, 2023, View Source [SID1234633295]). The webinar will take place on Thursday, August 10, 2023 at 8:30 AM PT / 11:30 AM ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will feature Ann M. Gillenwater, Professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center who will discuss the promising results of the novel combination and the potential implications for the current treatment landscape. Rakuten Medical’s management team will provide other business updates including, but not limited to, a Japan commercial update and the Global Phase 3 Trial of ASP-1929 in India.
Rakuten Medical’s technology consists of drug and device components and which Rakuten Medical hopes will become a potential 5th pillar of cancer treatment. The Alluminox platform has been shown in pre-clinical trials to target specific tumors as well as immunosuppressive cells for destruction with minimal effects on surrounding normal tissue.
ASP-1929 targeting EGFR is approved in Japan and has been marketed as Akalux since January 2021 for unresectable locally advanced or recurrent head and neck cancer. ASP-1929 received Fast Track designation from the U.S. FDA in January 2018, and is currently under investigation in a global Phase 3 clinical trial for recurrent head and neck cancer but outside of Japan, ASP-1929 has not yet been approved by any regulatory authority.
A live question and answer session will follow the formal presentation. Parties interested in participating in this event should click here to register and access the live webcast. Please note that practicing healthcare professionals and patients are not permitted to attend.